← Back

Aura Biosciences Inc

Aura Biosciences, Inc. is a clinical-stage biotechnology company that develops precision therapies for solid tumors. Its proprietary platform targets solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. The lead candidate, bel-sar, is in late-stage clinical development for primary choroidal melanoma and other ocular oncology indications, and in early-stage development for bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Country

USA

Sector

Biotechnology

Themes

Oncology Therapeutics

Price · split & dividend adjusted

News & notes moving AURA

AURA▼

Aura Biosciences reports Q2 GAAP EPS of -$0.48, missing estimates by $0.10

Aura Biosciences reported a second-quarter GAAP loss of $0.48 per share, missing analyst estimates by $0.10. As of June 30, 2026, the company held $323.8 million in cash, cash equivalents, and marketable securities. Management believes these resources are sufficient to fund operations into the first half of 2029.

AURA ▼

Seeking Alpha·38dRead more →